Let's Talk Prostate Cancer
A European expert group working to make sure every man with prostate cancer receives the right treatment and care at the right time.
Chaired by Members of the European Parliament and bringing together urologists, oncology nurses and patients, the campaign works to raise prostate cancer up the political agenda across Europe and globally.
About the campaign
The Let’s Talk Prostate Cancer (LTPC) Expert Group brings together stakeholders from key organisations in the field of prostate cancer and is chaired by Members of the European Parliament Romana Jerković, Laurent Castillo, András Kulja and Ondřej Dostál.
The group works to raise awareness of the challenges faced by people with prostate cancer in Europe and brings together EU level stakeholders with a shared interest in policy change, education and awareness, so that people with prostate cancer, and particularly those with advanced disease, receive the right treatment and care at the right time.
Members: European Association of Urology, European Association of Urology Nurses, European Oncology Nursing Society, Europa Uomo and East Galway & Midlands Cancer Support.
Prostate cancer in the EU
2 million1
people living with prostate cancer, the most common cancer in men
450,0003,4
new cases diagnosed in Europe in one year
107,0002,3
deaths in one year, one in ten male cancer deaths
The LTPC Digital Atlas
Compare prostate cancer incidence, mortality, survival, cancer care and quality of life across the EU 27 and the UK. Click a country on the map to open its profile.
Browse the atlas by theme
Resources
Policy recommendations
Position papers and recommendations from the Expert Group on prioritisation, health inequalities and the implementation of EU guidance.
Guidelines and policies
National and European clinical guidelines and cancer policies, country by country.
Reports and materials
Call to action, white papers, event reports and briefing papers to download and share.
Our expert group
The supporters
The activities of the Let’s Talk Prostate Cancer Expert Group are funded by Pfizer Inc., Amgen Inc. and MSD, which collectively contribute to and support the objectives of the Expert Group.
References
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Prostate Cancer UK. Separating fact from fiction: revealing the truth behind common prostate cancer myths. Accessible at https://prostatecanceruk.org/about-us/news-and-views/2019/7/prostate-cancer-mythbusting (last accessed October 2023)
2 Van Poppel, H et al. Prostate Cancer: Recommendations to lower the risk and mortality of the most frequent cancer in men. European Association of Urology. 2018. Accessible at https://uroweb.org/wp-content/uploads/EAU_WhitePaper_PCa_final.pdf (last accessed October 2023)
3 Van Poppel, H et al. Policy Paper on PSA Screening for Prostate Cancer. European Association of Urology. 2019. Accessible at http://epad.uroweb.org/wp-content/uploads/EAU_policy-briefing_PSA.pdf (last accessed October 2023)
4 Ferlay, J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer. 2018; 103:356-387. Accessible at https://doi.org/10.1016/j.ejca.2018.07.005 (last accessed September 2026)
2 Van Poppel, H et al. Prostate Cancer: Recommendations to lower the risk and mortality of the most frequent cancer in men. European Association of Urology. 2018. Accessible at https://uroweb.org/wp-content/uploads/EAU_WhitePaper_PCa_final.pdf (last accessed October 2023)
3 Van Poppel, H et al. Policy Paper on PSA Screening for Prostate Cancer. European Association of Urology. 2019. Accessible at http://epad.uroweb.org/wp-content/uploads/EAU_policy-briefing_PSA.pdf (last accessed October 2023)
4 Ferlay, J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer. 2018; 103:356-387. Accessible at https://doi.org/10.1016/j.ejca.2018.07.005 (last accessed September 2026)